share_log

Hopeful Golden Cross Forms On Biomarin Pharmaceutical's Chart

Hopeful Golden Cross Forms On Biomarin Pharmaceutical's Chart

希望的金十字出現在BioMarin製藥的圖表上
Benzinga Real-time News ·  2022/08/09 11:16

If history is any guide, there may be good fortune ahead for shares of Biomarin Pharmaceutical (NASDAQ:BMRN). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the stock.

如果歷史可以借鑑的話,蘋果的股票可能會有好運氣BioMarin製藥公司(納斯達克:寶馬)。在它的圖表上已經形成了一個所謂的“黃金十字”,並不令人驚訝,這可能對該股有利。

What To Know: Many traders use moving average crossover systems to make their decisions.

要知道的內容:許多交易員使用移動平均線交叉系統來做出決定。

When a shorter-term average price crosses above a longer-term average price, it could mean the stock is trending higher. If the short-term average price crosses below the long-term average price, it means the trend is lower.

當短期平均價格超過長期平均價格時,可能意味着該股正在走高。如果短期均價低於長期均價,則意味着走勢更低。

Why It's Important: The 50-day and the 200-day simple moving averages are commonly used.

為什麼它很重要:常用的是50日和200日簡單移動均線。

The golden cross occurs when the 50-day crosses above the 200-day. This could mean the long-term trend is changing.

當50天線在200天線上方時,黃金十字就會出現。這可能意味着長期趨勢正在改變。

That just happened with Biomarin Pharmaceutical, which is trading around $96.18 at publication time.

這種情況就發生在BioMarin製藥公司身上,該公司在出版時的股價約為96.18美元。

Remember: Seasoned investors don't blindly trade Golden Crosses.

記住:經驗豐富的投資者不會盲目交易金十字。

Instead, they use it as a signal to start looking for long positions based on other factors, like price levels and company fundamentals & events.

相反,他們把它作為一個信號,開始根據其他因素尋找多頭頭寸,比如價格水平和公司基本面和事件。

For seasoned investors, this is just a sign that it might be time to start considering possible long positions.

對於經驗豐富的投資者來説,這只是一個跡象,表明可能是時候開始考慮可能的多頭頭寸了。

With that in mind, take a look at Biomarin Pharmaceutical's past and upcoming earnings expectations:

考慮到這一點,讓我們來看看BioMarin製藥公司過去和即將到來的收益預期:

Quarter Q2 2022 Q1 2022 Q4 2021 Q3 2021
EPS Estimate 0.11   -0.32 -0.25
EPS Actual 0.59 0.17 -0.32 -0.20
Revenue Estimate 521.47M 507.52M 442.39M 435.32M
Revenue Actual 533.80M 519.36M 449.81M 408.74M
季度 Q2 2022 Q1 2022 Q4 2021 Q3 2021
每股收益預估 0.11 -0.32 -0.25
實際每股收益 0.59 0.17 -0.32 -0.20
收入預估 521.47M 507.52M 442.39M 435.32M
實際收入 533.80M 519.36M 449.81M 408.74M

Also consider this overview of Biomarin Pharmaceutical analyst ratings:

另請考慮BioMarin製藥分析師評級的概述:

Do you use the Golden Cross signal in your trading or investing? Share this article with a friend if you found it helpful!

你在交易或投資中使用金十字信號嗎?如果你覺得這篇文章對你有幫助,那就和朋友分享吧!

This article was generated by Benzinga's automated content engine and reviewed by an editor.

本文由Benzinga的自動內容引擎生成,並由編輯審閲。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論